cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Shahdevi Nandar Kurniawan
Contact Email
shahdevinandar@ub.ac.id
Phone
+62341-321297
Journal Mail Official
jphv@ub.ac.id
Editorial Address
Neurology Department, Faculty of Medicine, Brawijaya University Jl. JA Suprapto No. 2 Malang, Indonesia 65112
Location
Kota malang,
Jawa timur
INDONESIA
Journal of Pain, Vertigo and Headache
Published by Universitas Brawijaya
ISSN : 27233979     EISSN : 27233960     DOI : https://doi.org/10.21776/ub.jphv
Core Subject : Science,
Neuroscience
JPHV - Journal of Pain, Headache and Vertigo is a peer-reviewed and open access journal that focuses on promoting pain, headache and vertigo. This journal publishes original articles, reviews, and also interesting case reports. JPHV - Journal of Pain, Headache and Vertigo is an international scientific journal, published twice a year by PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia.
Arjuna Subject : Ilmu Syaraf - Neorologi
Articles 92 Documents
 5   6   7   8   9 
POST HERPETIC NEURALGIA Irsyah Dwi Rohmayanti; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 1 (2023): March
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.01.1

Abstract

Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that lasts 3 months or more after an outbreak of shingles. Herpes zoster, especially acute herpes zoster, is associated with the reactivation of the inactivated varicella zoster virus in individuals who have had chickenpox. PHN is associated with persistent and often refractory neuropathic pain. Patients may experience several types of pain, including deep pain, intolerable pain, burning, paroxysmal pain, stabbing pain, hyperalgesia, and allodynia. Pharmacological treatment of PHN may include a variety of drugs, including alpha-2 delta ligands (gabapentin and pregabalin), other anticonvulsants (carbamazepine), tricyclic antidepressants (amitriptyline, nortriptyline, doxepin), topical analgesics (5% lidocaine patch, capsaicin) tramadol, or other opioids. The sizeable side effect profile of commonly used oral drugs often limits their practical use, and a combination of topical and systemic agents may be required for optimal results. Doctors and other care providers must adapt treatment based on individual patient responses.
LEPROSY NEUROPATHY Fahrani Yossa Prachika; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 1 (2023): March
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.01.3

Abstract

Leprosy is a major cause of peripheral neuropathy in developing countries, affecting sensory, motor, and autonomic nerve function. Neuropathy complications can include sensory loss and muscle weakness. Impaired sensory nerve function is often the first symptom encountered in leprosy neuropathy. Early detection and treatment of neuropathy in leprosy are important to prevent disability.
HNP LUMBALIS Mega Yulia Rusmayanti; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 1 (2023): March
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.01.2

Abstract

Lumbar herniated nucleus pulposus (HNP) is a disorder characterized by local displacement of the disc beyond the anatomical boundaries of the intervertebral space causing pain, weakness or numbness, and/or tingling in myotomal or dermatomal distribution. HNP is the most common cause of low back pain. Lumbar HNP itself has several underlying etiologies, such as old age, excessive axial load, connective tissue disorders, and congenital abnormalities. Management of HNP can be carried out non-operatively or operatively, depending on the severity, the symptoms that arise, and the response to non-operative treatment.
MYASTHENIA GRAVIS Dewi Permata Sari; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 1 (2023): March
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2022.004.01.4

Abstract

Myasthenia gravis is an autoimmune disease of the postsynaptic membrane, especially acetylcholine receptors in the neuromuscular link of skeletal muscle. Patients with myasthenia gravis have a high number globally. The disease occurs due to a disorder that impairs the impulse connection between chemicals traveling from nerve endings and receptors. Clinical symptoms include weakness of the eye muscles (ptosis and diplopia), difficulty swallowing, and difficulty speaking. The diagnosis of myasthenia gravis is based on the patient's complaints obtained in the history, physical and neurological examination, and supporting examinations. The management that can be given is intravenous immunoglobulin (IVIg) therapy, plasma exchange (PE), corticosteroids given together with IVIg and PE, or acetylcholinesterase inhibitors. These treatments can determine the patient's prognosis. If the patient with myasthenia gravis is left to involve the respiratory muscles, then the patient's prognosis becomes worse. In addition, myasthenic crisis and cholinergic crisis may occur, which is a medical emergency.
PATHOPHYSIOLOGY IN CLUSTER HEADACHE: AN UPDATE Wa Ode Intan Nur Octina; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 1 (2023): March
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2022.004.01.5

Abstract

Cluster headache (CH) is a rare and very painful primary headache syndrome, with an estimated population prevalence of 0.12%. This condition can be episodic (ECH), lasting from 7 days to a year. A consensus statement from the European Headache Federation defines refractory CCH as a CCH with at least three severe attacks per week, even though at least three consecutive trials of adequate preventive care have been tested and managed with both acute and preventive treatment. Inhaled oxygen and subcutaneous sumatriptan are the two most effective acute treatment options for people with CH. Several preventive medications are also available, and the most effective is verapamil. However, most of these agents are not supported by strong clinical evidence. In some patients, this option may be ineffective, particularly in those with chronic CH. Surgical procedures for chronic refractory forms of disorder should then be considered.
LEPROSY NEUROPATHY : CLINICAL PRESENTATION Rizki Rahamatullah Noer; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 2 (2023): September
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.02.1

Abstract

Leprosy is a chronic infection caused by the bacteria M. leprae and causes damage to the skin and peripheral nervous system outside the brain and spinal cord, including the skin, mucous membranes of the nose, testicles, and eyes. This disease develops slowly over a long period, ranging from 6 months to 40 years, and can cause skin lesions and secondary defects. Leprosy is a common and treatable cause of peripheral neuropathy in many tropical and subtropical countries. Neuropathy is a condition that causes damage to the function and structure of the sensory, autonomic, and motor nerves in the peripheral nervous system. Complications of neuropathy can include loss of sensory abilities and muscle weakness. Impaired sensory nerve function is often the first symptom that appears in leprosy neuropathy. Therefore, early detection and treatment of neuropathy in leprosy is very important to prevent disability.
PERONEAL NERVE PALSY Vely Eva Meria; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 2 (2023): September
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.02.2

Abstract

Peroneal nerve palsy is a disorder caused by interference with the peroneal nerve. Usually, a drop foot is seen in patients who have peroneal nerve palsy. Basically, the causes of peroneal nerve palsy are multifactorial. Trauma, compression of the nerve, systemic disease, ischemia, and idiopathy are factors that cause peroneal nerve palsy. Management of peroneal nerve palsy can be done non-operatively or operatively, depending on the cause and severity.
DRUG INDUCED NEUROPATHY Anisa Syahfitri Hanum; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 2 (2023): September
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.02.3

Abstract

Neuropathy is a painful condition and originates from a variety of etiologies. Many drugs can cause neuropathy, which is known as Drug-Induced Neuropathy (DIN), which is included in iatrogenic cases. These drugs are chemotherapy agents, antimicrobials, cardiovascular drugs, psychotropics, anticonvulsants, etc. Not all neuropathies require pharmacological therapy, but simply stop therapy, and the complaints will improve (reversible). However, there are quite a few DINs with a “coasting" response neuropathy when DIN is stopped. This review synthesizes current clinical concepts regarding mechanisms, drug-induced neuropathy, and treatment options for drug-induced peripheral neuropathy.
GUILLAIN-BARRÉ SYNDROME Gyang Hanandita Gusti Putri; Nectarine Natasya Regitta Yasmin; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 2 (2023): September
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.02.4

Abstract

Guillain-Barré Syndrome (GBS) is an infection-preceded autoimmune disease attacking myelin sheath of neurons through molecular mimicry, causing neuron demyelination and conduction disruption. GBS is classified into four subtypes: Acute Inflammatory Demyelinating (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor Sensory Axonal Neuropathy (AMSAN), and Miller Fisher Syndrome. It affects spinal radix which resulted in polyneuropathy, showing mainly symptoms of ascending paresis of the extremity and areflexia. Cerebrospinal fluid evaluation is essential to distinguish GBS from its vast differential diagnosis, with main finding of albuminocytologic dissociation. GBS needs to be managed as fast as possible with intravenous immunoglobulin administration or fresh frozen plasma exchange due to its fast progression.
PATOFISIOLOGI MIASTENIA GRAVIS Devita Anggraeni Soeroso; Shahdevi Nandar Kurniawan
Journal of Pain, Headache and Vertigo Vol. 4 No. 2 (2023): September
Publisher : PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.jphv.2023.004.02.5

Abstract

Myasthenia Gravis (MG) is an autoimmune disease that disrupts transmission at the neuromuscular junction (NMJ). In myasthenia gravis, the immune system will attack the acetylcholine receptor (AChR) or other proteins involved in neuromuscular transmission or due to abnormalities in the thymus, which plays a role in immunity. This causes characteristic manifestations in the form of muscle weakness, which will improve after rest. So, in its management, the use of immunosuppressive therapy and removal of the thymus can be a therapeutic option depending on the type and severity of the disease.

Page 7 of 10 | Total Record : 92

 5   6   7   8   9 

Filter by Year

2020 2025


Reset
Filter By Issues
All Issue Vol. 6 No. 2 (2025): September Vol. 6 No. 1 (2025): March Vol. 5 No. 2 (2024): September Vol. 5 No. 1 (2024): March Vol. 4 No. 2 (2023): September Vol. 4 No. 1 (2023): March Vol. 3 No. 2 (2022): September Vol. 3 No. 1 (2022): March Vol. 2 No. 2 (2021): September Vol. 2 No. 1 (2021): March Vol. 1 No. 2 (2020): September Vol. 1 No. 1 (2020): March More Issue